4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide: a long-acting COX-2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
mavacoxib : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and 4-fluorophenyl groups, respectively. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine to treat pain and inflammation in dogs with degenerative joint disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9843089 |
| CHEMBL ID | 28527 |
| CHEBI ID | 76207 |
| SCHEMBL ID | 212699 |
| MeSH ID | M0553677 |
| Synonym |
|---|
| mavacoxib (usan) |
| D04863 |
| 170569-88-7 |
| 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide |
| chebi:76207 , |
| mavacoxib |
| pha 739,521 |
| trocoxil |
| pha-739521 |
| CHEMBL28527 , |
| 4-[5-(4-fluoro-phenyl)-3-trifluoromethyl-pyrazol-1-yl]-benzenesulfonamide |
| bdbm50057564 |
| unii-yft7x7sr77 |
| benzenesulfonamide, 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)- |
| yft7x7sr77 , |
| mavacoxib [usan:inn] |
| 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide |
| 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzene-1-sulfonamide |
| mavacoxib [mi] |
| mavacoxib [inn] |
| mavacoxib [ema epar veterinary] |
| mavacoxib [usan] |
| S6685 |
| SCHEMBL212699 |
| mavacoxibum |
| 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide |
| DTXSID90168880 |
| AKOS030241943 |
| HY-119447 |
| CS-0068402 |
| 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-benzenesulfonamide |
| Q6794110 |
| mfcd28138640 |
| NCGC00510931-01 |
| AT19475 |
| pha-739521; pha739521; pha 739521; pha 739,521; pha739,521; pha-739,521 |
| BCP15454 |
| AS-78391 |
| 4-[5-(4-fluorophenyl)-3-trifluoromethyl-1h-pyrazol-1-yl]benzenesulfonamide |
| c16h11f4n3o2s |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The treatments had a similar safety profile as evidenced by documented adverse events and summaries of clinical pathology parameters." | ( Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015) | 0.42 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetics of mavacoxib were evaluated in an absolute bioavailability study, a dose-proportionality study and a multi-dose study in young healthy adult laboratory Beagle dogs and in a multi-dose safety study in Beagle-sized laboratory Mongrel dogs." | ( The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. Boucher, JF; Cox, SR; Fielder, A; Hummel, BD; Krautmann, MJ; Lesman, SP; Marsh, S; Savides, M; Stegemann, MR, 2010) | 0.36 |
| " In this study, PK parameters and absolute oral bioavailability expressed as percentage (F%) of celecoxib (10 mg/kg BW), mavacoxib (4 mg/kg BW) and meloxicam (1 mg/kg BW) were determined following single oral (PO) and intravenous (IV) administration to cockatiels (Nymphicus hollandicus)." | ( Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus). Antonissen, G; Croubels, S; De Backer, P; De Baere, S; Devreese, M; Dhondt, L; Gehring, R; Goessens, T; Haesendonck, R, 2017) | 0.46 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " It has a long plasma half-life, requiring less frequent dosing and supporting increased owner compliance in treating their dogs." | ( The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. Argyle, DJ; Argyle, SA; Kamida, A; Morrison, KO; Pang, LY, 2014) | 0.4 |
| " The dosage schedule of mavacoxib for clinical use has been determined by owner and veterinary clinical assessments and is supported by integration of PK and PD preclinical data with clinical responses in canine disease models and in dogs with naturally occurring OA." | ( Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. Elliott, J; Lees, P; Michels, G; Pelligand, L; Stegemann, M; Toutain, PL, 2015) | 0.42 |
| " Of 139 dogs screened, 124 were suitable for study participation: 62 of which were dosed with mavacoxib and 62 with carprofen." | ( Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015) | 0.42 |
| " Further research is needed to make a dosing recommendation, including a pharmacodynamic study and investigating pharmacokinetics at different doses and multiple doses." | ( Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus). Carpenter, JW; Gardhouse, S; KuKanich, B; Wilson, SE, 2023) | 0.91 |
| Role | Description |
|---|---|
| non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
| cyclooxygenase 2 inhibitor | A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2. |
| non-narcotic analgesic | A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| pyrazoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 (µMol) | 25.7040 | 0.0003 | 2.1774 | 10.0000 | AID162176 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 (µMol) | 25.5000 | 0.0002 | 1.5574 | 10.0000 | AID161494; AID1709972 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 0.0409 | 0.0001 | 0.9950 | 10.0000 | AID160434; AID162507; AID162659; AID1709973 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 (µMol) | 0.0407 | 0.0005 | 0.4008 | 6.2000 | AID160595 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.02) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (27.78%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||